Radiation Oncology Residency

The Residency Program's objectives, facilities, faculty, prerequisites and application process.

Radiation Oncology Residency Training Program

The Residency Program's objectives, facilities, faculty, prerequisites and application process.

Introduction

The Radiation Oncology Residency Training Program at the 800-bed University of North Carolina Hospitals meets all the requirements of the American Board of Radiology (ABR) and is fully accredited by the American Medical Association's Accreditation Council for Graduate Medical Education (ACGME; see also UNC Healthcare's GME site). UNC Hospitals are the teaching hospitals of the UNC School of Medicine, located on the campus of the University of North Carolina at Chapel Hill. The first hospital in what later became known as UNC Hospitals and the UNC Health Care System was North Carolina Memorial Hospital, which opened on Sept. 2, 1952. 

The North Carolina Cancer Hospital, first opened in 2009,  is the state's major referral center for patients with cancer and has active oncology subspecialty programs in Radiation Oncology, Medical Oncology, Gynecologic Oncology, Urologic Oncology, Surgical and Breast Oncology, Thoracic Oncology, Head and Neck Cancer, Pediatric Oncology, and Neuro-Oncology. The Cancer Hospital is the clinical face of the UNC Lineberger Comprehensive Cancer Center, one of only 36 National Cancer Institute-designated comprehensive cancer centers in the United States, and nationally recognized for excellence in cutting-edge basic, clinical and translational cancer research.

Program Objectives

The Radiation Oncology Residency Training Program at UNC encompasses training in the fundamental principles of oncology, comprehensive cancer management, clinical radiation oncology, radiation treatment techniques, and research experience. The program offers didactic teaching of radiation therapy physics, dosimetry, treatment planning, biostatistics, radiation and cancer biology, and radiation pathology. Teaching is closely integrated with a multidisciplinary approach to state-of-the-art clinical management of cancer patients and investigative clinical research protocols.

The four-year residency program consists of a minimum of 36 months in clinical radiation oncology, electives (or equivalent) in medical oncology, surgical oncology, surgical pathology, diagnostic radiology and nuclear medicine, and radiation physics and dosimetry. In addition, a 6 month research elective supervised by a faculty preceptor is offered in areas such as radiation physics and 2- and 3-D treatment planning, molecular radiation biology, cancer biology, or specialized areas of clinical radiation oncology (IMRT, LDR/HDR brachytherapy, stereotactic radiosurgery, intraoperative radiotherapy, TBI). The Department has an ACGME-approved complement of eight residents, with two new residents accepted into the program each July.

Clinical training is provided in the standard care of common cancers as well as instruction in the management of unusual and complex oncologic problems. Over 2,500 patients are referred annually to the Department of Radiation Oncology. These include large numbers of patients with breast, gynecological, head and neck, bronchopulmonary, and lymphoreticular malignancies, along with patients with a wide range of other type of cancers. Non-oncologic conditions such as arteriovenous malformations are seen for stereotactic radiosurgery.

As residents advance through their training, they assume increasing responsibility for the evaluation and management of patient referrals, external beam and brachytherapy procedures, care of patients under treatment and follow-up care. Residents work closely with the attending radiation oncologists in all aspects of patient care and are instructed in the new areas of clinical trials, laboratory investigations, and to the development of investigational skills.

Departmental faculty have strong ties to the related disciplines of computer science, biomedical engineering, diagnostic imaging, genetics, nanotechnology, pathology and pharmacology, in addition to providing "in-house" instruction in radiation physics and radiation and cancer biology by nationally-recognized expert educators.

Facilities

The NC Cancer Hospital houses Radiation Oncology's clinical, physics and computing, healthcare engineering, educational and administrative programs. (The Cancer Biology Division is housed nearby in the Lineberger Comprehensive Cancer Center.)  The move to the Cancer Hospital consolidated all clinical oncology services and professional staff in a single location, and helped streamline operational efficiency. The move also facilitates unique education and training opportunities for our residents in the form of closer, more flexible interactions with faculty and peers in the other oncology specialties.

The 36,000 square foot Department of Radiation Oncology treats over 2,000 patients per year, and is an integral part of the UNC Lineberger Comprehensive Cancer Center. The Department has active research programs in clinical oncology, cancer biology, healthcare engineering and medical physics. The Department is an acknowledged world leader in the areas of computer-aided radiotherapy treatment planning and quality assurance/human factors research aimed at continuously improving patient safety.

In addition to our main facility in Chapel Hill, we have affiliate clinics in High Point and Lenoir, NC, as well as at Rex-UNC Healthcare, Raleigh, NC, a fully-owned component of UNC Radiation Oncology.  Our alliance with Rex Hospital further extends our reach with additional clinics in Wakefield, Clayton and Smithfield, NC.

The Department features the following treatment equipment and capabilities: three linear accelerators with MLC and independent jaws; a Calypso® IGRT system; a CT scanner on rails; a dedicated CT scanner for conformal treatment planning; a CyberKnife® stereotactic radiosurgery system; a TomoTherapy® system; a simulator; high and low dose rate brachytherapy equipment; and 3-D treatment planning workstations. These machines permit high energy X-ray, electron beam, and specialized radiation treatments.

A self-shielded, J.L. Shepherd Mark I irradiator is also available for radiation biology research, and serves as a campus-wide core facility for such.

Residents participate in an active brachytherapy program involving over 150 high and low dose rate radiation implant procedures annually for the treatment of gynecological, genitourinary, head and neck, esophagus, lung and other malignancies. A full array of radioactive sources for interstitial and intracavitary radiation therapy is available including iridium-192, iodine-125 and phosphorus-32.

Other specialized treatment programs include intraoperative radiation therapy and total body irradiation for bone marrow transplantation.

Advanced treatment planning systems on computer work stations are used for all types of external beam, interstitial and intracavitary treatment plans that are routinely used in the clinical management of patients. The Department is at the forefront of research and development of sophisticated 3-D imaging and treatment planning for clinical applications, and residents routinely carry out advanced 3-D conformal treatment planning.

Radiation Oncology residents have their own work area equipped with personal computers which are part of the Department's extensive local area network. This network provides ready access to Medline, the Health Sciences Library, UNC Hospitals laboratories and the Tumor Registry, and to the internet.

Conferences

Didactic teaching courses with lectures once or twice a week are held in radiation physics and dosimetry (annually), and radiation and cancer biology (biennially). Residents participate in teaching, patient care and research in the Department, as well as attend both in-house and multidisciplinary conferences of the UNC Clinical Cancer Program. The in-house conferences include:

  1. daily morning conferences where residents make case presentations, discuss clinical treatment planning, and review simulations
  2. weekly chart rounds where current patients receiving radiotherapy are presented
  3. weekly radiation oncology clinical seminars
  4. monthly journal clubs with both resident and faculty participation
  5. monthly morbidity and mortality conferences
  6. monthly faculty research conferences
  7. less frequent conferences:  Visiting Professor lectures; oncology grand rounds; mock oral boards sessions; In-Training exam review; "best of" medical or scientific conference reports

Regular multidisciplinary conferences are held in conjunction with the Breast Oncology, Gynecologic Oncology, Medical Oncology, Surgical Oncology, Head and Neck Surgery, Pediatric Oncology, Neuro-Oncology and Gastrointestinal Oncology programs. Residents also have an opportunity to attend a variety of oncology-related lectures and symposia elsewhere on the UNC campus.

Research Programs

The Department of Radiation Oncology is actively engaged in clinical investigation programs through national cooperative research groups including the Gynecologic Oncology Group (GOG), Cancer and Acute Leukemia Group B (CALGB), National Surgical Adjuvant Breast Program (NSABP), Radiation Therapy Oncology Group (RTOG), and the Children's Cancer Study Group (CCSG).  Intramurally, faculty members are actively engaged in studies of normal tissue toxicity, radiation-drug interactions, and combination therapy with surgery and radiation.  Other areas of clinical interest include heath care outcomes research, and human factors/operations research and LEAN management principles with the ultimate goal of improving patient safety (our Department is a national leader in this area).

The Division of Cancer Biology has as its emphasis the study of molecular mechanisms of radiation action, new drug discovery and characterization, and basic cancer biology.

The Division of Physics and Computing develops and implements state-of-the-art imaging tools that allow radiation oncologists to better understand the various dose delivery systems and to aid in the development of newer techniques of dose delivery. The Division also has an active cancer nanotechnology program.

The Division of Healthcare Engineering has a broad focus, studying the impact of transformational leadership, Lean-based management practices, design of physical spaces and processes, and cognitive/behavioral factors on workers’ ability to perform their jobs well, with the ultimate goal of improving efficiency, reliability, safety and quality of radiation therapy treatment.

An additional factor that has major implications for the institutional cancer programs is the University Cancer Research Fund (UCRF). This fund, developed by the state legislature, commits an initial $25M per year, increasing to $50M per year, in support of cancer research efforts at UNC, including the development of clinical excellence in delivery of care to cancer patients and substantial research infrastructure support. A second resource is the North Carolina Translational and Clinical Sciences (NC TraCS) Institute based at UNC, part of a national consortium of medical research institutions that together offer programs and services supporting researchers through all phases of the "bench to bedside" process of translational research. Our Department benefits from both of these programs in terms of our clinical and basic research efforts that, in turn, offer additional training opportunities for our residents.

Faculty

The Departmental faculty include nineteen ABR-certified radiation oncologists (including those at our affiliates), ten ABR-certified medical physicists, four radiation/cancer biologists, two faculty members devoted largely to education, two faculty members involved in LEAN management and human factors research, and joint faculty from the Department of Computer Science. Most are actively involved in the clinical care of oncology patients, teaching and/or research. In addition to mentoring radiation oncology and medical physics residents, faculty members are also involved in education and training programs for medical students, graduate students and postdoctoral fellows, radiation therapists and medical dosimetrists. They have ongoing research programs, hold leadership roles in national clinical protocol development, and make regular contributions to scientific conferences at the local, regional, national and international levels.

Program Prerequisites

In order to be eligible for our radiation oncology residency training program, an applicant must:

  • Be a US citizen or hold a valid US immigration VISA that permits employment in the United States. The UNC Department of Radiation Oncology does not provide sponsorship for any type of immigration VISA.
  • Successfully complete all United States Medical Licensing Examination (USMLE) requirements or, if a foreign medical graduate, all Educational Commission for Foreign Medical Graduates (ECFMG) requirements.
  • Successfully complete a one year clinical internship in a hospital approved by the ACGME prior to entering the residency training program.

Application Process

Each year, two new residents meeting all program prerequisites are accepted. Anywhere from 30-40 applicants are selected for personal interviews. Interviews are conducted in groups of 6-8 applicants during the months of November, December and January. Having completed a prior rotation during medical school at the UNC Department of Radiation Oncology does not automatically guarantee an interview for a residency position.

Positions are offered through the National Resident Matching Program (NRMP), and applications must be submitted using the Electronic Residency Application Service (ERAS) system.

For the Fall, 2015 interview season, we will have two open residency positions (start date: July 1, 2017).

Additional Information

You may obtain additional information by contacting the Program Coordinator:

Ms. Rebecca Moore

Phone: (984) 974-8418

 

 

 

Radiation Oncology Residents

 

Current Residents (2015-2016)

 

     

 

For the Fall, 2015 interview season, we will have two open residency positions (start date: July 1, 2017). 

 

Recent Alumni

 

    Dr. Seth Miller

    Coastal Carolina Radiation Oncology, New Bern, NC

     

    Dr. Gregg Goldin

    Radiation Therapy Associates of Western North Carolina (21st Century Oncology), Asheville, NC


    Dr. Noam VanderWalde

    Assistant Professor, University of Tennessee and The West Clinic Radiation Oncology Group, Memphis, TN


    Dr. Nate Sheets

    Assistant Professor, UNC/Rex Radiation Oncology, Raleigh, NC

       

      Dr. Dan Higginson

      Clinical Translational Research Fellow, Memorial Sloan-Kettering Cancer Center, New York, NY

         

        Dr. Lewis Rosenberg

        Cancer Centers of North Carolina, Raleigh, NC

           

          Dr. Randy Kimple

          Assistant Professor, Dept. of Human Oncology, University of Wisconsin School of Medicine, Madison, WI

             

            Dr. Steve Harris

            Seacoast Cancer Center, Wentworth-Douglass Hospital, Dover, NH

               

              Dr. Jim Apisarnthanarax

              Associate Professor, Dept. of Radiation Oncology, University of Washington School of Medicine, Seattle, WA

                Dr. Aaron Falchook (PGY 5)

                Education

                • Undergraduate:  University of Florida, Gainesville, FL
                • Medical School: University of Florida College of Medicine, Gainesville, FL
                • Internship:  University of North Carolina Hospitals, Chapel Hill, NC

                 

                Honors and Awards

                Medical School:

                  • Genevra Todd and Henry E. Meleney Award for outstanding academic achievement, 2009
                  • International Medical Mission Service Award to the Dominican Republic, 2009

                Residency:

                  • ASCO Merit Award; Annual Meeting of the American Society of Clinical Oncology, June, 2013
                  • ASTRO Scientific Abstract Award; Annual Meeting of the American Society for Radiation Oncology, September, 2013
                  • ASCO Merit Award; Annual Meeting of the American Society of Clinical Oncology, June, 2014

                   

                  Research Interests

                  Image guidance for prostate cancer; regional management of head and neck cancer; patterns of care and utilization of healthcare resources for surgical, medical, and radiation oncology treatment of malignancy

                   

                  Publications

                  (as of 2/17/15)

                  • Falchook AD, Hendrix LH, Chen RC. Guideline-discordant use of imaging during work-up of newly diagnosed prostate cancer. J Oncol Pract 2015 Feb 10. [Epub ahead of print], PMID: 25670199.
                  • Falchook AD, Chen RC. Association between certificate of need legislation and radiation therapy use among elderly patients with early cancers. Int J Radiat Oncol Biol Phys 2015 Feb 1;91(2):448-450.  PMID: 25636768.
                  • Falchook AD, Zevallos JP, Chera BS. Increased risk of salivary gland cancer among women with a previous cancer diagnosis. Head Neck 2015 Jan 12. [Epub ahead of print], PMID: 25581457.
                  • Jagsi R, Falchook AD, Hendrix LH, Curry H, Chen RC. Adoption of hypofractionated radiation therapy for breast cancer after publication of randomized trials. Int J Radiat Oncol Biol Phys 2014 Dec 1;90(5):1001-1009. PMID: 25539365.
                  • Mosaly PR, Mazur L, Miller S, Eblan M, Falchook A, Goldin G, Burkhart K, LaChapelle D, Adams R, Chera B, Marks LB. Application of human factors analysis and classification system model to event analysis in radiation oncology. Prac Rad Onc 2014 October 24. [Epub ahead of print], PMID: 25413409.
                  • Falchook AD, Salloum RG, Hendrix LH, Chen RC. Use of bone scan during initial prostate cancer workup, downstream procedures, and associated Medicare costs. Int J Radiat Oncol Biol Phys 2014;89(2):243-248. PMID: 24321784
                  • Falchook A, Tepper J. Rectal cancer genomics. Semin Colon Rectal Surg 2014 Mar;25(1):13-18. DOI: 10.1053/j.scrs.2013.09.010
                  • Falchook AD, Zagar TM. A case report of stereotactic radiosurgery in a patient with Ehlers-Danlos syndrome. Rep Pract Oncol Radiother 2013;18(4):241-244. PMID: 24416559.
                  • Falchook A, Dagan R, Morris C, Mendenhall W. Elective neck dissection for second primary after previous definitive radiotherapy. Am J Otolaryngology 2013;33(2):199-204. PMID: 21658804.
                  • Vargas C, Saito A, Hsi W, Indelicato D, Falchook A, Zengm Q, Oliver K, Keole S, Dempsey J.  Cine-magnetic resonance imaging assessment of interfraction motion for prostate cancer patient supine or prone with and without a rectal balloon. Am J Clin Onc 2010;33:11-16.  PMID:19730351.
                  • Vargas C, Falchook A, Indelicato D, Yeung A, Henderson R, Olivier K, Keole S, Williams C, Li Z, Palta J. Proton therapy for prostate cancer treatment employing online image guidance and an action level threshold. Am J Clin Onc 2009;32:180-186.  PMID: 19307953.
                  • Yeung A, Vargas C, Falchook A, Louis D, Olivier K, Keole S, Yeung D, Mendenhall N, Li Z. Dose-volume differences for computed tomography and magnetic resonance imaging segmentation and planning for prostate cancer therapy. Int J Radiat Onc Biol Phys 2008;72:1426-1433. PMID: 18762391
                  • Vargas C, Wagner M, Mahajan, C, Indelicato D, Fryer A, Falchook A, Horne D, Chellini A, McKenzie C, Lawlor P, Li Z, Lin L, and Keole S. Proton therapy coverage for prostate cancer treatment. Int J Radiat Onc Biol Phys 2008;70:1492-1501. PMID:18374228.

                   

                  Meeting Abstracts/Presentations

                  • Falchook A, Hendrix LH, VanderWalde NA, Zagar TM, Jones EL, Jagsi R, Chen RC. Adoption of hypofractionated radiotherapy (HyRT) for ductal carcinoma in situ (DCIS): A SEER-Medicare study. American Society of Clinical Oncology Quality Care Symposium, Boston, MA, Oct 18, 2014. (Oral presentation.) 
                  • Falchook A, Chen RC. Association between certificate of need (CON) legislation and radiotherapy use among elderly patients with early cancers: a population-based examination. American Society of Clinical Oncology Quality Care Symposium, Boston, MA, Oct 18, 2014. (Poster presentation.)  
                  • Falchook A, Hendrix LH, Curry HA, Chen RC, Jagsi R. Adoption of intensity modulated radiotherapy (IMRT) in early stage breast cancer patients receiving hypofractionated and conventionally fractionated radiation in the US. American Society for Radiation Oncology Annual Meeting, San Francisco, CA, Sept 14-17, 2014.  (Poster presentation.)
                  • Mosaly PR, Mazur L, Miller SM, Eblan MJ, Falchook A, Goldin GH, Marks LB.  Assessing the applicability and reliability of the human factors analysis and classification system (HFACS) to the analysis of good catches in radiation oncology. American Society for Radiation Oncology Annual Meeting, San Francisco, CA, Sept 14-17, 2014.  (Poster presentation.) 
                  • Falchook A, Hendrix L, VanderWalde N, Zagar T, Jones E, Jagsi R, Chen R. Adoption of hypofractionated radiotherapy (HyRT) for ductal carcinoma in situ (DCIS): a SEER-Medicare study. American Society of Clinical Oncology Annual Meeting, Chicago, IL June 3, 2014. (Oral presentation.)
                  • Falchook AD, Hendrix LH, VanderWalde NA, Zagar TM, Jones E, Jagsi R, Chen RC. Adoption of hypofractionated radiotherapy for early-stage invasive breast cancer after publication of randomized trials.  American Society of Clinical Oncology Annual Meeting, Chicago, IL, June 3, 2014. (Oral presentation.)
                  • Mazur L, Mosaly P, Falchook A, Eblan M, Boyle M, Frohlich F, Marks L. Quantification of physicians' workload using eye-tracking and EEG-based data. Industrial and Systems Engineering Research Conference, Montreal, Canada, May 2014. (Oral presentation.)
                  • Falchook A, Hendrix L, Chen R. Clinical implications of bone scan underuse for patients with high-risk prostate cancer (CaP). Poster Presentation at American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, San Francisco, CA, January 30, 2014. (Poster presentation.)
                  • Falchook AD, Salloum RG, Hendrix LH, Chen RC. Multiple pathology reviews in prostate cancer diagnosis, prevalence of use in the Medicare population and cost implications. (Abstract.)  American Society for Radiation Oncology Annual Meeting, Atlanta, GA, September, 2013. (Oral presentation.)
                  • Falchook AD, Salloum RG, Hendrix LH, Chen RC. Use of bone scans during initial prostate cancer (CaP) workup, downstream procedures, and associated Medicare costs. (Abstract.)  American Society of Clinical Oncology Annual Meeting, Chicago, IL, June, 2013.  (Poster presentation.)
                  • Yadava P, Falchook A, Hughes J.  Cationic sulfhydryl containing surfactant for siRNA delivery.  (Abstract.)  American Association of Pharmaceutical Scientists Annual Meeting, San Francisco, CA,  May, 2005. (Poster presentation.)


                    Aaron Falchook (2012)

                    Dr. Aaron Falchook
                    Aaron Falchook (2012)
                    Full-size image: 401.2 KB | View image View Download image Download

                    Available sizes

                    Use these links to add this image to your page.

                    mini 133 x 200 thumb 85 x 128 large 512 x 768 listing 10 x 16 tile 42 x 64 preview 266 x 400 icon 21 x 32

                    Michael Eblan (2012)

                    Michael Eblan, M.D.
                    Michael Eblan (2012)
                    Full-size image: 478.9 KB | View image View Download image Download

                    Available sizes

                    Use these links to add this image to your page.

                    mini 133 x 200 thumb 85 x 128 large 512 x 768 listing 10 x 16 tile 42 x 64 preview 266 x 400 icon 21 x 32

                    Dr. Michael Eblan (PGY 5)

                    Education

                    • Undergraduate:  University of Virginia, Charlottesville, VA
                    • Medical School:  University of Pennsylvania School of Medicine, Philadelphia, PA
                    • Internship:  University of North Carolina Hospitals, Chapel Hill, NC

                     

                    Honors and Awards

                    • Undergraduate:
                      • Madison House Volunteer Service Award
                      • Center for Global Health University Scholar Award
                      • Phi Beta Kappa Honor Society
                      • National Institutes of Health Intramural Research Training Award
                    • Medical School:
                      • Ruth L. Kirschstein National Research Service Award
                    • Residency:
                      • American Society for Radiation Oncology Advocacy Day Travel Grant, March, 2014
                      • ASCO Oncology Trainee Travel Award; Annual Meeting of the American Society of Clinical Oncology, June, 2014

                     

                    Publications

                    (as of 8/25/15)

                    • Min Y, Caster JM, Eblan MJ, Wang AZ. Clinical translation of nanomedicine. Chem Rev 2015 Jun 19. [Epub ahead of print]. PMID: 26088284.
                    • Mosaly PR, Mazur L, Miller S, Eblan M, Falchook A, Goldin G, Burkhart K, LaChapelle D, Adams R, Chera B, Marks LB. Application of human factors analysis and classification system model to event analysis in radiation oncology. Prac Rad Onc 2015 March-April;5:113-119. PMID: 25413409.

                    • Eblan MJ, VanderWalde NA, Zeman EM, Jones E. Hypofractionation for breast cancer: lessons learned from our neighbors to the north and across the pond. Oncology (Williston Park) 2014 Jun;28(6):536-546. [Non-refereed.] PMID: 25134333.
                    • Eblan MJ, Corradetti MN, Lukens JN, Xanthopoulos E, et al. Comparative effectiveness of intensity-modulated radiotherapy and conventional conformal radiotherapy in the treatment of prostate cancer after radical prostatectomy.  JAMA Intern Med 2013;173(12):1136-1143. PMID: 23689844.
                    • Eblan MJ, Wang AZ. Improving chemoradiotherapy with nanoparticle therapeutics. Transl Cancer Res 2013 Aug 1;2(4):320-329. PMID: 25429359
                    • Eblan MJ, Corradetti MN, Lukens JN, et al. Brachial plexopathy in apical non-small cell lung cancer treated with definitive radiation: dosimetric analysis and clinical implications.  Int J Radiat Oncol Biol Phys 2013;85(1):175-181. PMID: 22658442
                    • Eblan MJ, Corradetti MN, Lukens JN, Xanthopoulos E, Mitra N, Christodouleas JP, Grover S, Fernandes AT, Langer CJ, Evans TL, Stevenson J, Rengan R, Apisarnthanarax S. Brachial plexopathy in apical non-small cell lung cancer treated with definitive radiation: dosimetric analysis and clinical implications. International Journal of Radiation Oncology Biology Physics. 2013 Jan;85(1):175-181. PMID: 22658442.
                    • Eblan MJ, Cengel KA.  Biology of proton therapy: Old and new considerations. In J.M. Metz, C.R. Thomas (Ed.), Proton Therapy: Radiation Medicine Rounds. New York, NY. Demos Medical Publishing. 2010 Dec; Volume 1, Number 3. 
                    • Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, Barbosa ER, Bar-Shira A, Berg D, Bras J, Brice A, Chen CM, Clark LN, Condroyer C, De Marco EV, Dürr A, Eblan MJ, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. New Eng J Med 2009 Oct; 361(17):1651-1661. PMID: 19846850.
                    • Goker-Alpan O, Wiggs EA, Eblan MJ, Benko W, et al. Cognitive outcome in treated patients with chronic neuronopathic Gaucher disease. J Pediatr 2008 Jul;153(1):89-94. PMID: 18571543.
                    • Ziegler SG, Eblan MJ, Gutti U, Hruska KS, et al. Glucocerebrosidase mutations in Chinese subjects from Taiwan with sporadic Parkinson disease. Molec Genet Metab 2007 Jun;9(2):195-200. PMID: 17462935.
                    • Goker-Alpan O, Giasson BI, Eblan MJ, Nguyen J, Hurtig HI, Lee VM, Trojanowski JQ, Sidransky E. Glucocerebrosidase mutations are an important risk factor for Lewy body disorders. Neurol 2006 Sep;67(5):908-910. PMID: 16790605.
                    • Eblan MJ, Scholz S, Stubblefield B, Gutti U, Goker-Alpan O, Hruska KS, Singleton AB, Sidransky E. Glucocerebrosidase mutations are not found in association with LRRK2 G2019S in subjects with Parkinsonism. Neurosci Lett 2006 Aug;404(1-2):163-165.
                    • Holleran WM, Ziegler SG, Goker-Alpan O, Eblan MJ, Elias PM, Schiffmann R, Sidransky E. Skin abnormalities as an early predictor of neurologic outcome in Gaucher disease. Clin Genet 2006 Apr;69(4):355-357. PMID: 16630170
                    • Eblan MJ, Nguyen J, Ziegler SG, Lwin A, Hanson M, Gallardo M, Weiser R, De Lucca M, Singleton A, Sidransky E. Glucocerebrosidase mutations are also found in subjects with early-onset parkinsonism from Venezuela. Movement Disord 2006 Feb;21(2):282-283. PMID: 16261622.
                    • Eblan MJ, Goker-Alpan O, Sidransky E. Perinatal lethal Gaucher disease: a distinct phenotype along the neuronopathic continuum. Fetal Pediatr Path 2005 Jul;24(4-5):205-222. PMID: 16396828.  
                    • Eblan MJ, Walker JM, Sidransky E. The glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. New Eng J Med 2005 Feb;352(7):728-731. PMID: 15716572.


                    Meeting Abstracts/Presentations

                    • Eblan MJ, Myung JH, Caster JM, Miller SM, Moore DT, Chera BS, Seungpyo HS, Wang A. Prospective characterization of circulating tumor cells (CTCs) in head and neck cancer patients receiving definitive radiotherapy. American Society of Clinical Oncology Annual Meeting, Chicago, IL, May 29 - June 2, 2015. (Poster presentation.)
                    • Mosaly PR, Mazur L, Miller SM, Eblan MJ, Falchook A, Goldin GH, Marks LB.  Assessing the applicability and reliability of the human factors analysis and classification system (HFACS) to the analysis of 'good catches' in radiation oncology. American Society for Radiation Oncology Annual Meeting, San Francisco, CA, Sept 14-17, 2014. (Poster presentation.) 
                    • Eblan MJ, Caster JM, Shah AR, Lee CN and Jones EL.  Effect of internal mammary vessel irradiation on outcomes of free flap breast reconstruction in patients treated with mastectomy and radiation therapy for breast cancer. American Society for Radiation Oncology Annual Meeting, San Francisco, CA, Sept 14-17, 2014. (Poster presentation.) 
                    • Mazur L, Mosaly P, Falchook A, Eblan M, Marks L. Towards better understanding of cognitive workload during physician-computer interaction.  International Conference on Applied Human Factors and Ergonomics (AHFE), Krakow, Poland, July, 2014. (Oral presentation.)
                    • Eblan MJ, Chen RC, Laura H. Hendrix LH, Jones E. Population-based analysis of mortality over time in endometrial cancer.  American Society of Clinical Oncology Annual Meeting, Chicago, IL, May 29 - June 2, 2014. (Poster presentation.) 
                    • Eblan MJ, Sanoff HK, McRee AJ, O'Neil BH, Garmey EG, Hennessy MG, Eliasof S, Tepper JE, Wang A.  A phase IB/II study of neoadjuvant chemoradiotherapy with CRLX101 and capecitabine for locally advanced rectal cancer. American Society of Clinical Oncology Annual Meeting, Chicago, IL, May 29 - June 2, 2014. (Poster presentation.)
                    • Mazur L, Mosaly P, Falchook AEblan M, Boyle M, Frohlich F, Marks L. Quantification of physicians' workload using eye-tracking and EEG-based data. Industrial and Systems Engineering Research Conference, Montreal, Canada, May 2014. (Oral presentation.)
                    • Mosaly P, Mazur LM, Miller S, Eblan M, Jones E.  Applying human factors analysis and classification system (HFACS) to the analysis of ‘good catches’ in radiation oncology.  American Society for Radiation Oncology Annual Meeting, Atlanta, GA, September, 2013. (Poster presentation.)
                    • Mosaly P, Mazur LM, Miller S, Eblan M, Jones E, Burkhardt K, Adams R, Rockwell J, Chera B, Marks L. Applying the human factors analysis and classification system (HFACS) model to the analysis of radiation therapy safety events.  American Society for Radiation Oncology Joint Workshop on Technology for Innovation in Radiation Oncology, National Institutes of Health, Bethesda, MD, June, 2013. (Oral presentation.)

                    Joe Caster (2013)

                    Joe Caster (2013)
                    Full-size image: 583.5 KB | View image View Download image Download

                    Available sizes

                    Use these links to add this image to your page.

                    mini 133 x 200 thumb 85 x 128 large 512 x 768 listing 10 x 16 tile 42 x 64 preview 266 x 400 icon 21 x 32

                    Jordan Holmes (2014)

                    Jordan Holmes (2014)
                    Full-size image: 512.2 KB | View image View Download image Download

                    Available sizes

                    Use these links to add this image to your page.

                    mini 133 x 200 thumb 85 x 128 large 512 x 768 listing 10 x 16 tile 42 x 64 preview 266 x 400 icon 21 x 32

                    Gregory Judy (2014)

                    Gregory Judy (2014)
                    Full-size image: 652.1 KB | View image View Download image Download

                    Available sizes

                    Use these links to add this image to your page.

                    mini 133 x 200 thumb 85 x 128 large 512 x 768 listing 10 x 16 tile 42 x 64 preview 266 x 400 icon 21 x 32

                    Kyle Wang (2014)

                    Kyle Wang (2014)
                    Kyle Wang (2014)
                    Full-size image: 650.1 KB | View image View Download image Download

                    Available sizes

                    Use these links to add this image to your page.

                    mini 133 x 200 thumb 85 x 128 large 512 x 768 listing 10 x 16 tile 42 x 64 preview 266 x 400 icon 21 x 32

                    Dominic Moon (2015)

                    Dominic Moon (2015)
                    Full-size image: 1.2 MB | View image View Download image Download

                    Available sizes

                    Use these links to add this image to your page.

                    mini 133 x 200 thumb 85 x 128 large 512 x 768 listing 10 x 16 tile 42 x 64 preview 266 x 400 icon 21 x 32


                    Full-size image: 1.2 MB | View image View Download image Download

                    Available sizes

                    Use these links to add this image to your page.

                    mini 133 x 200 thumb 85 x 128 large 512 x 768 listing 10 x 16 tile 42 x 64 preview 266 x 400 icon 21 x 32